Skip to main content


Fig. 7 | Cardiovascular Diabetology

Fig. 7

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Fig. 7

MACE by occurrence of hypoglycaemic event. Data presented for the overall population and the subgroup of patients with a history of CVD (CVD history). n is the number of patients with an event; N is the number of patients in treatment group. CI confidence interval, CTRL control, CVD cardiovascular disease, DAPA dapagliflozin, HR hazard ratio, hypo hypoglycaemia, MACE major adverse cardiovascular events (cardiovascular death, myocardial infarction and stroke), p–y = patient–years

Back to article page